Drug Identification System

PillID

← Drug Encyclopedia 🌙

Uses & FDA Indications

Levetiracetam is FDA-approved as both monotherapy and adjunctive treatment for several seizure types across a wide age range.

FDA-Approved Uses

• Partial-onset (focal) seizures — monotherapy in patients aged 6 months and older; adjunctive therapy in adults and children aged 1 month and older
• Myoclonic seizures in juvenile myoclonic epilepsy (JME) — adjunctive therapy in adults and adolescents aged 12 and older
• Primary generalized tonic-clonic seizures — adjunctive therapy in adults and children aged 6 and older

Off-Label Uses

• Status epilepticus (intravenous formulation)
• Seizure prophylaxis after traumatic brain injury or neurosurgery
• Alcohol withdrawal seizure prevention
• Restless legs syndrome

How It Works

Levetiracetam binds to a protein called synaptic vesicle glycoprotein 2A (SV2A), which is expressed on the membranes of synaptic vesicles throughout the brain. SV2A plays a role in the exocytosis of neurotransmitters from vesicles. By modulating SV2A, levetiracetam is thought to reduce the release of neurotransmitters in hyperexcitable neuronal circuits, thereby damping the abnormal neuronal synchronization that underlies seizures.

This mechanism is entirely different from sodium channel blockers (phenytoin, carbamazepine), GABA enhancers (benzodiazepines, valproate), or calcium channel modulators (gabapentin). The selectivity for SV2A contributes to levetiracetam's clean drug-interaction profile — it does not inhibit or induce major liver enzymes, making it safe to combine with many other medications, including other anticonvulsants and oral contraceptives.

Side Effects

Common

• Somnolence and fatigue
• Dizziness
• Nasopharyngitis (cold-like symptoms)
• Irritability, mood changes, and emotional lability
• Headache
• Decreased appetite
• Coordination difficulties

Serious

• Behavioral and psychiatric effects — aggression, agitation, hostility, anxiety, depression, and psychosis; colloquially called "Keppra rage"; can be severe enough to require switching medications
• Suicidal ideation and behavior — class-wide FDA warning for all anticonvulsants; monitor for mood changes especially in the early weeks of therapy
• Serious skin reactions — rare cases of SJS, TEN, and DRESS reported
• Blood dyscrasias — leukopenia, neutropenia, and pancytopenia have been reported; monitor CBC if symptoms arise
• Withdrawal seizures — abrupt discontinuation can precipitate seizures; taper slowly

Drug Interactions

Drug / Class	Interaction	Clinical Significance
Probenecid	Inhibits renal tubular secretion of levetiracetam's active metabolite, nearly doubling drug exposure	Moderate — monitor for levetiracetam toxicity; combination rarely encountered clinically
CNS depressants (benzodiazepines, opioids, alcohol, sedating antihistamines)	Additive sedation, dizziness, and psychomotor impairment	Moderate — use caution; advise patients to avoid alcohol
Methotrexate	Case reports of levetiracetam reducing methotrexate clearance	Low–Moderate — monitor in oncology settings
Oral contraceptives	No clinically meaningful interaction; levetiracetam does not induce hepatic enzymes and does not reduce contraceptive efficacy	None — an advantage over enzyme-inducing anticonvulsants
Other anticonvulsants	Minimal pharmacokinetic interactions due to absence of hepatic enzyme induction or inhibition; some additive sedation may occur	Low — generally safe to combine; monitor for additive CNS effects
Valproate	Minor reduction in valproate levels observed in some studies; combination is clinically widely used	Low — clinically insignificant in most patients
Antipsychotics / mood stabilizers	Levetiracetam's psychiatric side effects may be compounded in patients with pre-existing mood disorders; pharmacokinetic interactions minimal	Low–Moderate — monitor behavioral side effects more closely

Warnings & Contraindications

Key Precautions

• Behavioral monitoring: Patients and caregivers should be informed of the risk of mood changes, irritability, and aggression; prompt reporting is important
• Psychiatric history: Patients with pre-existing depression, anxiety, or psychosis may be at higher risk for behavioral side effects
• Renal impairment: Clearance is reduced; use lower doses in patients with creatinine clearance below 80 mL/min
• Pregnancy: Among the anticonvulsants, levetiracetam has a relatively reassuring safety profile; it is increasingly preferred over older agents for women of childbearing age, though no anticonvulsant is completely without risk in pregnancy
• Do not discontinue abruptly: Gradual tapering required to avoid withdrawal seizures

Frequently Asked Questions

What is "Keppra rage" and how common is it?

Keppra rage is a colloquial term for the behavioral and mood side effects — irritability, aggression, emotional lability, and anger outbursts — that some patients experience on levetiracetam. It is a recognized phenomenon reported in clinical trials and real-world experience. Studies suggest that clinically significant mood or behavioral changes occur in roughly 10–15% of patients, though rates vary. The mechanism is not fully understood. For some patients, supplementing with pyridoxine (vitamin B6) has been reported to help, though evidence is limited. If severe, switching to a different anticonvulsant may be warranted.

Does levetiracetam interact with birth control?

No — this is one of levetiracetam's important advantages. Unlike enzyme-inducing anticonvulsants such as carbamazepine, phenytoin, and topiramate, levetiracetam does not induce liver enzymes and does not reduce the effectiveness of hormonal contraceptives. Women with epilepsy who require anticonvulsant therapy can use standard hormonal contraception without concern about reduced efficacy when taking levetiracetam.

Can levetiracetam be given intravenously?

Yes. An IV formulation is available and is widely used in hospital settings for status epilepticus, seizure prophylaxis after brain injury or surgery, and when a patient cannot take oral medications. The IV form has the same efficacy as oral levetiracetam and allows 1:1 conversion between routes. It is often chosen over phenytoin/fosphenytoin in acute settings due to its simpler monitoring requirements and fewer drug interactions.

Is levetiracetam safe during pregnancy?

Levetiracetam has one of the better safety profiles among anticonvulsants in pregnancy, with lower rates of major malformations compared to valproate or topiramate in registry data. It is increasingly used as a preferred agent for women with epilepsy who are pregnant or planning pregnancy. However, no anticonvulsant is completely without risk, and the decision to continue any anticonvulsant during pregnancy involves weighing seizure control risks against fetal exposure risks — a decision made with a neurologist and often a maternal-fetal medicine specialist.

→ Anticonvulsant Side Effects Guide → Epilepsy Medications Guide